RT Journal Article
SR Electronic
T1 Past SARS-CoV-2 infection elicits a strong immune response after a single vaccine dose
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.03.14.21253039
DO 10.1101/2021.03.14.21253039
A1 Chahla, Rossana Elena
A1 Hernán Tomas-Grau, Rodrigo
A1 Inés Cazorla, Silvia
A1 Ploper, Diego
A1 Pingitore, Esteban Vera
A1 López, Mónica Aguilar
A1 Aznar, Patricia
A1 Alcorta, Malena
A1 del Mar Vélez, Eva María
A1 Stagnetto, Agustín
A1 Ávila, César Luís
A1 Maldonado-Galdeano, Carolina
A1 Benjamín Socias, Sergio
A1 Heinze, Dar
A1 Navarro, Silvia Adriana
A1 Llapur, Conrado
A1 Costas, Dardo
A1 Flores, Isolina
A1 Apfelbaum, Gabriela
A1 Mostoslavsky, Raúl
A1 Mostoslavsky, Gustavo
A1 Perdigón, Gabriela
A1 Chehín, Rosana Nieves
YR 2021
UL http://medrxiv.org/content/early/2021/03/24/2021.03.14.21253039.abstract
AB We hypothesized that in individuals with previous SARS-CoV-2 infection, the first vaccine dose would work as a booster, eliciting a faster and more intense immune response. We herein describe antibody responses to the first and second doses of Gam-COVID-Vac (SPUTNIK V) vaccine in health personnel of Tucumán, Argentina, with previous COVID-19 and compared it with uninfected personnel. Individuals with anti-SARS-CoV-2 titers at baseline showed significantly higher responses to the first dose than people with no prior history of disease (p <0.0001), with titers higher to those registered after the second dose in the control group, representing a clear secondary antibody response. This suggests that a single dose of SPUTNIK V for people with previous SARS-CoV-2 infection could contribute to a better use of available doses.One-Sentence Summary First vaccine dose in subjects with prior COVID19 elicits a higher antibody response than two doses in uninfected individualsCompeting Interest StatementThe authors have declared no competing interest.Funding StatementThis work was funded by Ministerio de Salud Publica de Tucuman (REC, RTG, SIC, DP, EVP, MAL, PA, MA, EMdMV, AS, CLA, CMG, SBS, DH, SAN, CLL, DC, IF, GP, RNC) Argentinean Research Council-CONICET grants PIP 722 and 806 (RNC, CMG) Argentinean Research Agency grants MINCYT PICT-2018-3379 and PICT2018-02989 (DP, SBS) Tucuman National University grants (PIUNT-UNT D644/1 and D624 (CLA, CMG) Fundacion Florencio Fiorini (DP) Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The protocol used in the present study was opportunely submitted to the: -Comite de Etica en Investigacion- Direccion de Investigacion en Salud- SiProSa (Sistema Provincial de Salud). Address: Virgen de la Merced 189-1st floor- (San Miguel de Tucuman) -4000-Argentine. The protocol was approved by Research Department and Ethics Committee (SiProSa-Tucuman Health Ministery). Identification: Dictamen CEI 29-2020 Contact: +54-9-0381-4526585-ext:120 See all information at: https://msptucuman.gov.ar/wordpress/wp-content/uploads/2021/03/Expediente-N3929-410-P2020-Seroconversin-post-vacunacin-para-SARS-CoV-2-immune-response-after-a-single-vaccine-dose.pdf https://msptucuman.gov.ar/wordpress/wp-content/uploads/2021/03/03.Serocoversion-DICTAMEN-19-1-2021.pdf https://msptucuman.gov.ar/wordpress/wp-content/uploads/2021/03/FCI-SeroconversionRCSfinal.pdf All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yesall data are available on demand